REFERENCES
- van Leeuwaarde RS, Ahmad S, Links TP, et al. Von Hippel-Lindau Syndrome. 2000 May 17 [Updated 2018 Sep 6]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2021. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1463/
- Rasmussen A, Alonso E, Ochoa A, et al. Uptake of genetic testing and long-term tumor surveillance in von Hippel-Lindau disease. BMC Med Genet. 2010;11(1):4. doi:https://doi.org/10.1186/1471-2350-11-4.
- Abbott AB, Knickelbein JE, Wiley HE, et al. Ocular von Hippel-Lindau disease – clinical characteristics and future directions. Expert Rev Ophthalmol. 2016 Aug 25;11(5):329–337. doi:https://doi.org/10.1080/17469899.2016.1224652.
- Maher ER, Neumann HP, Richard S. von Hippel–Lindau disease: a clinical and scientific review. Eur J Human Genet. 2011;19(6):617. doi:https://doi.org/10.1038/ejhg.2010.175.
- Wiley HE, Schachat AP, Chew EY. Hemangioblastoma of the Retina and Von Hippel–Lindau Disease. In: Schachat AP, ed. Retina. Vol 3. 6 ed. Edinburgh: Elsevier; 2018:2427–2437
- Ruppert MD, Gavin M, Mitchell KT, et al. Ocular manifestations of von Hippel-Lindau disease. Cureus. 2019 Aug 4;11(8):e5319.
- Aronow ME, Wiley HE, Gaudric A, et al. Von Hippel-Lindau disease: update on pathogenesis and systemic aspects. Retina (Philadelphia, Pa). 2019 May 14;39:2243–2253. doi:https://doi.org/10.1097/IAE.0000000000002555.
- Chittiboina P, Lonser RR. Von Hippel-Lindau disease. Handb Clin Neurol. 2015;132:139–156.
- Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 1993;260(5112):1317–1320. doi:https://doi.org/10.1126/science.8493574.
- Chan -C-C, Collins ABD, Chew EY. Molecular pathology of eyes with von Hippel–lindau (VHL) disease – a review. Retina (Philadelphia, Pa). 2007;27(1):1.
- Ohh M, Park CW, Ivan M, et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel–Lindau protein. Nat Cell Biol. 2000;2(7):423–427. doi:https://doi.org/10.1038/35017054.
- Wang Y, Abu-Asab MS, Shen D, et al. Upregulation of hypoxia-inducible factors and autophagy in von Hippel–Lindau-associated retinal hemangioblastoma. Graefes Arch Clin Exp Ophthalmol. 2014;252(8):1319–1327. doi:https://doi.org/10.1007/s00417-014-2660-0.
- Nielsen SM, Rhodes L, Blanco I, et al. Von Hippel-Lindau disease: genetics and role of genetic counseling in a multiple neoplasia syndrome. J Clin Oncol. 2016;34(18):2172–2181. doi:https://doi.org/10.1200/JCO.2015.65.6140.
- Singh AD, Shields CL, Shields JA. von Hippel–Lindau disease. Surv Ophthalmol. 2001;46(2):117–142. doi:https://doi.org/10.1016/S0039-6257(01)00245-4.
- Haddad NM, Cavallerano JD, Silva PS. Von hippel-lindau disease: a genetic and clinical review. Semin Ophthalmol. 2013 Sep-Nov;28(5–6):377–386. doi:https://doi.org/10.3109/08820538.2013.825281.
- Chan CC, Collins AB, Chew EY. Molecular pathology of eyes with von Hippel-Lindau (VHL) disease: a review. Retina (Philadelphia, Pa). 2007 Jan;27(1):1–7.
- Nordstrom-O’Brien M, Van Der Luijt RB, Van Rooijen E, et al. Genetic analysis of von Hippel-Lindau disease. Hum Mutat. 2010;31(5):521–537. doi:https://doi.org/10.1002/humu.21219.
- Friedrich CA. Genotype–phenotype correlation in von Hippel-Lindau syndrome. Hum Mol Genet. 2001;10(7):763–767. doi:https://doi.org/10.1093/hmg/10.7.763.
- Ong KR, Woodward ER, Killick P, et al. Genotype–phenotype correlations in von Hippel-Lindau disease. Hum Mutat. 2007;28(2):143–149. doi:https://doi.org/10.1002/humu.20385.
- Maher ER. Von Hippel-Lindau disease. Curr Mol Med. 2004;4(8):833–842. doi:https://doi.org/10.2174/1566524043359827.
- Clifford SC, Maher ER. Von Hippel-Lindau disease: clinical and molecular perspectives. Adv Cancer Res. 2001;82:85–105. doi:https://doi.org/10.1016/S0065-230X(01)82003-0
- Harris AL. von Hippel-Lindau syndrome: target for anti-vascular endothelial growth factor (VEGF) receptor therapy. Oncologist. 2000;5(Suppl 1):32–36. doi:https://doi.org/10.1634/theoncologist.5-suppl_1-32.
- Richard S, Gardie B, Couvé S, et al. Von Hippel–Lindau: how a rare disease illuminates cancer biology. Semin Cancer Biol. 2013 Feb 01;23(1):26–37. doi:https://doi.org/10.1016/j.semcancer.2012.05.005.
- Penn JS, Madan A, Caldwell RB, et al. Vascular endothelial growth factor in eye disease. Prog Retin Eye Res. 2008;27(4):331–371.
- Caprara C, Grimm C. From oxygen to erythropoietin: relevance of hypoxia for retinal development, health and disease. Prog Retin Eye Res. Jan 01, 2012;31(1):89–119.
- Selvam S, Kumar T, Fruttiger M. Retinal vasculature development in health and disease. Prog Retin Eye Res. 2018 Mar 01;63:1–19.
- Das A, McGuire PG. Retinal and choroidal angiogenesis: pathophysiology and strategies for inhibition. Prog Retin Eye Res. 2003 Nov 01;22(6):721–748. doi:https://doi.org/10.1016/j.preteyeres.2003.08.001.
- Sytkowski AJ. Erythropoietin, von Hippel-Lindau protein and renal cancer: molecular basis for the paraneoplastic syndrome of erythrocytosis. Wspolczesna Onkologia-Contemp Oncol. 2005; 9(3):116–122.
- Waldmann TA, Levin EH, Baldwin M. The association of polycythemia with a cerebellar hemangioblastoma: the production of an erythropoiesis stimulating factor by the tumor. Am J Med. 1961 Aug 01;31(2):318–324. doi:https://doi.org/10.1016/0002-9343(61)90120-6.
- Shively SB, Falke EA, Li J, et al. Developmentally arrested structures preceding cerebellar tumors in von Hippel-Lindau disease. Mod Pathol. 2011;24(8):1023–1030. doi:https://doi.org/10.1038/modpathol.2011.61.
- Vortmeyer AO, Tran MGB, Zeng W, et al. Evolution of VHL tumourigenesis in nerve root tissue. J Pathol. 2006;210(3):374–382. doi:https://doi.org/10.1002/path.2062.
- Liang X, Shen D, Huang Y, et al. Molecular pathology and CXCR4 expression in surgically excised retinal hemangioblastomas associated with von Hippel–Lindau disease. Ophthalmology. 2007;114(1):147–156. doi:https://doi.org/10.1016/j.ophtha.2006.05.068.
- Binderup ML, Bisgaard ML, Harbud V, et al. Von Hippel-Lindau disease (vHL). National clinical guideline for diagnosis and surveillance in Denmark. 3rd edition. Dan Med J. 2013 Dec;60(12):B4763.
- Magee MA, Kroll AJ, Lou PL, et al. editors. Retinal capillary hemangiomas and von Hippel-Lindau disease. Semin Ophthalmol. 2006;21:143–150. Taylor & Francis. doi:https://doi.org/10.1080/08820530500350712.
- Poulsen ML, Budtz-Jorgensen E, Bisgaard ML. Surveillance in von Hippel-Lindau disease (vHL). Clin Genet. 2010 Jan;77(1):49–59. doi:https://doi.org/10.1111/j.1399-0004.2009.01281.x.
- Hes F, Van Der Luijt R, Lips C. Clinical management of von Hippel–Lindau (VHL) disease. Neth J Med. 2001;59(5):225–234. doi:https://doi.org/10.1016/S0300-2977(01)00165-6.
- Mettu P, Agrón E, Samtani S, et al. Genotype-phenotype correlation in ocular von Hippel-Lindau (VHL) disease: the effect of missense mutation position on ocular VHL phenotype. Invest Ophthalmol Vis Sci. 2010;51(9):4464–4470. doi:https://doi.org/10.1167/iovs.10-5223.
- Wong WT, Agrón E, Coleman HR, et al. Genotype-phenotype correlation in von Hippel-Lindau disease with retinal angiomatosis. Arch Ophthalmol. 2007;125(2):239–245. doi:https://doi.org/10.1001/archopht.125.2.239.
- Webster AR, Maher ER, Moore AT. Clinical characteristics of ocular angiomatosis in von Hippel-Lindau disease and correlation with germline mutation. Arch Ophthalmol. 1999;117(3):371–378. doi:https://doi.org/10.1001/archopht.117.3.371.
- Chew EY. Ocular manifestations of von Hippel-Lindau disease: clinical and genetic investigations. Trans Am Ophthalmol Soc. 2005;103:495–511.
- Malecha MA, Haik BG, Morris WR. Capillary hemangioma of the optic nerve head and juxtapapillary retina. Arch Ophthalmol. 2000;118:289–291.
- Şahin Atik S, Solmaz AE, Öztaş Z, et al. Von Hippel-Lindau disease: the importance of retinal hemangioblastomas in diagnosis. Turk J Ophthalmol. 2017;47(3):180–183. doi:https://doi.org/10.4274/tjo.90912.
- McCabe CM, Flynn HW Jr, Shields CL, et al. Juxtapapillary capillary hemangiomas: clinical features and visual acuity outcomes. Ophthalmology. 2000;107(12):2240–2248. doi:https://doi.org/10.1016/S0161-6420(00)00422-X.
- Toy BC, Agrón E, Nigam D, et al. Longitudinal analysis of retinal hemangioblastomatosis and visual function in ocular von Hippel-Lindau disease. Ophthalmology. 2012;119(12):2622–2630. doi:https://doi.org/10.1016/j.ophtha.2012.06.026.
- Wong WT, Agrón E, Coleman HR, et al. Clinical characterization of retinal capillary hemangioblastomas in a large population of patients with von Hippel–Lindau disease. Ophthalmology. 2008;115(1):181–188. doi:https://doi.org/10.1016/j.ophtha.2007.03.009.
- Sen M, Shields CL, Honavar SG, et al. Coats disease: an overview of classification, management and outcomes. Indian J Ophthalmol. 2019;67(6):763–771. doi:https://doi.org/10.4103/ijo.IJO_841_19.
- Cahuzac A, Scemama C, Mauget-Faÿsse M, et al. Retinal arterial macroaneurysms: clinical, angiographic, and tomographic description and therapeutic management of a series of 14 cases. Eur J Ophthalmol. 2016;26(1):36–43.
- Rojanaporn D. Vasoproliferative Tumors of the Retina. Ocular Oncology. Singapore: Springer; 2019. p. 67-75.
- Hadjistilianou D, De Francesco S, Menicacci C, et al. Vasoproliferative retinal tumors in children and adults. Acta Ophthalmol. 2019;97(S263)
- Singh AD, Nouri M, Shields CL, et al. Retinal capillary hemangioma: a comparison of sporadic cases and cases associated with von Hippel-Lindau disease. Ophthalmology. 2001;108(10):1907–1911. doi:https://doi.org/10.1016/S0161-6420(01)00758-8.
- Wong WT, Yeh S, Chan -C-C, et al. Retinal vascular proliferation as an ocular manifestation of von Hippel-Lindau disease. Arch Ophthalmol. 2008;126(5):637–643. doi:https://doi.org/10.1001/archopht.126.5.637.
- Pulido JS, Dalvin LA, Olsen TW, et al. Peripheral retinal nonperfusion using widefield imaging with von Hippel-Lindau disease. Int J Retina Vitreous. 2018;4:36. doi:https://doi.org/10.1186/s40942-018-0139-6.
- Campochiaro PA. Molecular pathogenesis of retinal and choroidal vascular diseases. Prog Retin Eye Res. 2015 Nov 01;49:67–81. doi:https://doi.org/10.1016/j.preteyeres.2015.06.002.
- Hayreh SS. Neovascular glaucoma. Prog Retin Eye Res. 2007 Sept;26(5):470–485. doi:https://doi.org/10.1016/j.preteyeres.2007.06.001.
- Rodrigues GB, Abe RY, Zangalli C, et al. Neovascular glaucoma: a review. Int J Retina Vitreous. 2016 Nov 14;2(1):26. doi:https://doi.org/10.1186/s40942-016-0051-x.
- Shazly TA, Latina MA. Neovascular glaucoma: etiology, diagnosis and prognosis. Semin Ophthalmol. 2009 Jan 01;24(2):113–121. doi:https://doi.org/10.1080/08820530902800801.
- Zhang SX, Ma J-X. Ocular neovascularization: implication of endogenous angiogenic inhibitors and potential therapy. Prog Retin Eye Res. 2007 Jan;26(1):1–37.
- Vail D. Angiomatosis retinae, eleven years after diathermy coagulation. Trans Am Ophthalmol Soc. 1957;55:217.
- Sigelman J. Retinal diseases: Pathogenesis, laser therapy, and surgery. Retinal diseases: pathogenesis, laser therapy, and surgery. Boston: Little, Brown; 1984. p. 316.
- Venkatesh P, Takkar B. Proposed classification system for retinal capillary angiomatosis. Ophthalmic Res. 2019;61(2):115–119. doi:https://doi.org/10.1159/000494498.
- Maheshwari A, Newman H, Finger PT. Ocular Von Hippel-Lindau disease. In: Khetan V, ed. Intraocular Tumors. Singapore: Springer Singapore; 2020:145–151.
- Goes F, Benozzi J. Ultrasonography of haemangioma of the optic disc. Bull Soc belge d’ophtalmologie. 1980;190:87.
- Chelala E, Dirani A, Fadlallah A. Intravitreal anti-VEGF injection for the treatment of progressive juxtapapillary retinal capillary hemangioma: a case report and mini review of the literature. Clin Ophthalmol. 2013;7:2143–2146. doi:https://doi.org/10.2147/OPTH.S53243.
- Karimi S, Nikkhah H, Ahmadieh H, et al. Intravitreal injection of propranolol for the treatment of retinal capillary hemangioma in a case of Von Hippel-Lindau. Retin Cases Brief Rep. 2018. doi:https://doi.org/10.1097/ICB.0000000000000718.
- Krivosic V, Kamami-Levy C, Jacob J, et al. Laser photocoagulation for peripheral retinal capillary hemangioblastoma in von Hippel-Lindau disease. Ophthalmol Retina. 2017;1(1):59–67. doi:https://doi.org/10.1016/j.oret.2016.08.004.
- Campos Polo R, Rubio Sánchez C, García Guisado DM, et al. Bilateral juxtapapillary retinal capillary haemangioma: usefulness of aflibercept in the management of its complications. Archivos Soc Esp Oftalmología (English Edition). 2017 Oct 01;92(10):477–480. doi:https://doi.org/10.1016/j.oftale.2017.07.003.
- Grigoropoulos VG, Nikolaidis P, Emfietzoglou I, et al. Evolution of a juxtapapillary von Hippel–Lindau tumour examined by optical coherence tomography. Clin Exp Optometry. 2012;95(2):237–240. doi:https://doi.org/10.1111/j.1444-0938.2012.00720.x.
- Sagar P, Shanmugam PM, Konana VK, et al. Optical coherence tomography angiography in assessment of response to therapy in retinal capillary hemangioblastoma and diffuse choroidal hemangioma. Indian J Ophthalmol. 2019;67(5):701–703. doi:https://doi.org/10.4103/ijo.IJO_1429_18.
- Say EAT, Shah SU, Ferenczy S, et al. Optical Coherence Tomography of Retinal and Choroidal Tumors. J Ophthalmol. 2011 2011/07/18;2011
- Chou BW, Nesper PL, Jampol LM, et al. Solitary retinal hemangioblastoma findings in OCTA pre- and post-laser therapy. Am J Ophthalmol Case Rep. 2018;10:59–61. doi:https://doi.org/10.1016/j.ajoc.2018.01.036.
- Santhirasegaram K, Wehrmann K, Feucht N, et al. Von Hippel-Lindau disease: OCTA findings in retinal hemangioma [Von Hippel-Lindau-syndrome: OCT-A Befund bei retinalen Hämangiomen]. Ophthalmologe. 2017;114(7):650–652. doi:https://doi.org/10.1007/s00347-016-0347-0.
- Smid LM, Van Overdam KA, Davidoiu V, et al. Classification and treatment follow-up of a juxtapapillary retinal hemangioblastoma with optical coherence tomography angiography. Am J Ophthalmol Case Rep. 2019 Sept 01;15:100472. doi:https://doi.org/10.1016/j.ajoc.2019.100472.
- Albiñana V, Escribano RMJ, Soler I, et al. Repurposing propranolol as a drug for the treatment of retinal haemangioblastomas in von Hippel-Lindau disease. Orphanet J Rare Dis. 2017 Jun 29;12(1):122. doi:https://doi.org/10.1186/s13023-017-0664-7.
- Annesley JW, Leonard B, Shields J, et al. Fifteen year review of treated cases of retinal angiomatosis. Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol. 1977;83(3 Pt 1):446–53.
- Kim H, Yi JH, Kwon HJ, et al. Therapeutic outcomes of retinal hemangioblastomas. Retina. 2014;34(12):2479–2486. doi:https://doi.org/10.1097/IAE.0000000000000254
- Lefevre A, Mathis T, Denis P, et al. Retinal hemangioblastoma: treatment strategy and long-term follow-up in a retrospective cohort [Hémangioblastomes rétiniens: stratégie thérapeutique et suivi à long terme dans une cohorte rétrospective]. J Fr Ophtalmol. 2018;41(2):164–169. doi:https://doi.org/10.1016/j.jfo.2017.07.004.
- Ucan Gunduz G, Gelisken O, Yalcinbayir O, et al. Laser photocoagulation, intravitreal anti-VEGF, and vitreous surgery for the treatment of juxtapapillary retinal capillary hemangioma [Case Report]. Indian J Ophthalmol. 2019 Dec 1;67(12):2104–2106. doi:https://doi.org/10.4103/ijo.IJO_1799_18.
- Schmidt D, Natt E, Neumann H. Long-term results of laser treatment for retinal angiomatosis in von Hippel-Lindau disease. Eur J Med Res. 2000;5:47–58.
- Ziemssen F, Voelker M, Inhoffen W, et al. Combined treatment of a juxtapapillary retinal capillary haemangioma with intravitreal bevacizumab and photodynamic therapy. Eye. 2007 Aug 01;21(8):1125–1126. doi:https://doi.org/10.1038/sj.eye.6702896.
- Mennel S, Meyer CH, Callizo J. Combined intravitreal anti-vascular endothelial growth factor (Avastin) and photodynamic therapy to treat retinal juxtapapillary capillary haemangioma. Acta Ophthalmol. 2010;88(5):610–613. doi:https://doi.org/10.1111/j.1755-3768.2008.01449.x.
- Garcia-Arumí J, Sararols LH, Cavero L, et al. Therapeutic options for capillary papillary hemangiomas. Ophthalmology. 2000;107(1):48–54. doi:https://doi.org/10.1016/s0161-6420(99)00018-4.
- Baba T, Kitahashi M, Kubota-Taniai M, et al. Subretinal hemorrhage after photodynamic therapy for juxtapapillary retinal capillary hemangioma. Case Rep Ophthalmol. 2011;2(1):134–139. doi:https://doi.org/10.1159/000328384.
- Mashayekhi A, Shields CL, Shields JA. Transient increased exudation after photodynamic therapy of intraocular tumors. Middle East Afr J Ophthalmol. 2013;20(1):83. doi:https://doi.org/10.4103/0974-9233.106400.
- Sachdeva R, Dadgostar H, Kaiser PK, et al. Verteporfin photodynamic therapy of six eyes with retinal capillary haemangioma. Acta Ophthalmol. 2010;88(8):e334–e340. doi:https://doi.org/10.1111/j.1755-3768.2010.02008.x.
- Schmidt-Erfurth UM, Kusserow C, Barbazetto IA, et al. Benefits and complications of photodynamic therapy of papillary capillary hemangiomas. Ophthalmology. 2002;109(7):1256–1266. doi:https://doi.org/10.1016/S0161-6420(02)01059-X.
- Cerman E, Çekiç O. Clinical use of photodynamic therapy in ocular tumors. Surv Ophthalmol. 2015;60:557–574.
- Tsai F-Y, Lau L-I, Chen S-J, et al. Persistent exudative retinal detachment after photodynamic therapy and intravitreal bevacizumab injection for multiple retinal capillary hemangiomas in a patient with von Hippel–Lindau disease. J Chin Med Assoc. 2014;77(1):52–56. doi:https://doi.org/10.1016/j.jcma.2013.09.001.
- Krzystolik K, Stopa M, Kuprjanowicz L, et al. Pars plana vitrectomy in advanced cases of von Hippel–Lindau eye disease. Retina (Philadelphia, Pa). 2016;36(2):325–334. doi:https://doi.org/10.1097/IAE.0000000000000707.
- Gaudric A, Krivosic V, Duguid G, et al. Vitreoretinal surgery for severe retinal capillary hemangiomas in von Hippel–Lindau disease. Ophthalmology. 2011;118(1):142–149. doi:https://doi.org/10.1016/j.ophtha.2010.04.031.
- Avci R, Yilmaz S, Inan UU, et al. Vitreoretinal surgery for patients with severe exudative and proliferative manifestations of retinal capillary hemangioblastoma because of von Hippel-Lindau disease. Retina (Philadelphia, Pa). 2017;37(4):782–788. doi:https://doi.org/10.1097/IAE.0000000000001240.
- Karacorlu M, Hocaoglu M, Sayman Muslubas I, et al. Therapeutic outcomes after endoresection of complex retinal capillary hemangioblastoma. Retina (Philadelphia, Pa). 2018;38(3):569–577. doi:https://doi.org/10.1097/IAE.0000000000001562.
- Aiello LP, George DJ, Cahill MT, et al. Rapid and durable recovery of visual function in a patient with von Hippel-Lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor su5416. Ophthalmology. 2002;109(9):1745–1751. doi:https://doi.org/10.1016/S0161-6420(02)01159-4.
- Girmens J-F, Erginay A, Massin P, et al. Treatment of von Hippel-Lindau retinal hemangioblastoma by the vascular endothelial growth factor receptor inhibitor SU5416 is more effective for associated macular edema than for hemangioblastomas. Am J Ophthalmol. 2003;136(1):194–196. doi:https://doi.org/10.1016/S0002-9394(03)00101-6.
- Jennens RR, Rosenthal MA, Lindeman GJ, Michael M. Complete radiological and metabolic response of metastatic renal cell carcinoma to SU5416 (semaxanib) in a patient with probable von Hippel-Lindau syndrome. Urol Oncol. 2004 May-Jun;22(3):193–6. doi:https://doi.org/10.1016/j.urolonc.2004.01.011
- Wong WT, Liang KJ, Hammel K, et al. Intravitreal ranibizumab therapy for retinal capillary hemangioblastoma related to von Hippel-Lindau disease. Ophthalmology. 2008;115(11):1957–1964. e3. doi:https://doi.org/10.1016/j.ophtha.2008.04.033.
- Slim E, Antoun J, Kourie HR, et al. Intravitreal bevacizumab for retinal capillary hemangioblastoma: a case series and literature review. Can J Ophthalmol. 2014;49(5):450–457. doi:https://doi.org/10.1016/j.jcjo.2014.07.007.
- Dahr SS, Cusick M, Rodriguez-Coleman H, et al. Intravitreal anti-vascular endothelial growth factor therapy with pegaptanib for advanced von Hippel-Lindau disease of the retina. Retina (Philadelphia, Pa). 2007;27(2):150–158. doi:https://doi.org/10.1097/IAE.0b013e318030a290.
- Hrisomalos FN, Maturi RK, Pata V. Long-term use of intravitreal bevacizumab (avastin) for the treatment of von Hippel-Lindau associated retinal hemangioblastomas. Open Ophthalmol J. 2010;4:66. doi:https://doi.org/10.2174/1874364101004010066.
- Michels S, Messmer E, Sutter F, et al. [Intravitreal anti-VEGF therapy for capillary hemangioblastomas in von Hippel-Lindau disease]. Klin Monbl Augenheilkd. 2008 Apr;225(4):292–294. doi:https://doi.org/10.1055/s-2008-1027175.
- De Klerk TA, Steel DHW. Use of intravitreal bevacizumab in a patient with a Von Hippel-Lindau-associated retinal haemangioblastoma of the optic nerve head: a case report. J Med Case Rep. 2008;2:182. doi:https://doi.org/10.1186/1752-1947-2-182.
- Sharma, A., Kumar, N., Kuppermann, B.D. et al. Brolucizimab—leading an era of structural revolution for long-term VEGF suppression. Eye 34, 611–613 (2020)
- Moisseiev, E., Loewenstein, A. Abicipar pegol—a novel anti-VEGF therapy with a long duration of action. Eye 34, 605–606 (2020). https://doi.org/10.1038/s41433-019-0584–y
- Smithwick E, Stewart MW. Designed ankyrin repeat proteins: a look at their evolving use in medicine with a focus on the treatment of chorioretinal vascular disorders. Antiinflamm Antiallergy Agents Med Chem. 2017;16(1):33–45. doi:https://doi.org/10.2174/1871523016666170502115816.
- Schmidt-Erfurth U, Sadeghipour A, Gerendas BS, et al. Artificial intelligence in retina. Prog Retin Eye Res. 2018 Nov 01;67:1–29. doi:https://doi.org/10.1016/j.preteyeres.2018.07.004.